Mobia Medical 任命 Myriam J. Curet 加入提名与公司治理委员会
Mobia Medical, Inc. (0001489993) (Filer)
Mobia Medical 于 10 月 16 日提交 Form 8-K/A,补充披露董事会于 10 月 15 日任命 Myriam J. Curet, M.D. 加入提名与公司治理委员会,任命即时生效。该修订仅补充委员会任命事项,原 8-K 的其他披露保持不变。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 30, 2026 |
Mobia Medical, Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware |
001-43275 |
20-8573833 |
||
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
2802 Flintrock Trace Suite 226 |
||||
Austin, Texas |
78738 |
|||
(Address of Principal Executive Offices) |
(Zip Code) |
|||
Registrant’s Telephone Number, Including Area Code: 855 628-9375 |
N/A |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Trading |
|
||
Common Stock, $0.01 par value per share |
MOBI |
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
This amendment supplements Item 5.02 of Mobia Medical, Inc.’s (“Mobia”) Current Report on Form 8-K filed on August 3, 2026, solely to report the committee appointment described below. All other disclosures in that report remain unchanged.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) Election of Directors.
On October 15, 2026, Mobia’s Board of Directors appointed Myriam J. Curet, M.D., to serve as a member of its nominating and corporate governance committee, effective immediately.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MOBIA MEDICAL, INC. |
|||
Date: |
October 16, 2026 |
By: |
/s/ Richard Foust |
Richard Foust |
来源:SEC EDGAR · 本站存档